tm logo
AGONY
REGISTERED

on 22 Feb 2022

Last Applicant/ Owned by

CANADIAN NEUTRICEUTICAL HEALTH INC.

25 Shepherd Ave w, suite 300Toronto

ONTARIO

CA

M2N6S8

Serial Number

1930746 filed on 15th Nov 2018

Registration Number

TMA1120617 registered on 22nd Feb 2022

Registration expiry Date

22nd Feb 2032

Correspondent Address

dba Trademark AngelSuite 521,6-2557 Dougall Avenue,Windsor,

ONTARIO

CA

N8X1T5

AGONY

Trademark usage description

anti-diabetic pharmaceuticals; antidiabetic pharmaceuticals; anti-epileptic pharmaceutical preparations; herbal supplements for the treatment of the r Read More

Classification Information


Class [005]
Anti-diabetic pharmaceuticals; antidiabetic pharmaceuticals; anti-epileptic pharmaceutical preparations; herbal supplements for the treatment of the respiratory system; herbal supplements for use in dermatology, namely, dermatitis, eczema, psoriasis; injectable pharmaceutical contraceptives; mineral supplements; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple scle; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical products for ophthalmological use; mineral supplements; vitamin and mineral dietary supplements; vitamin and mineral food supplements; vitamin and mineral preparations; vitamin and mineral supplements; vitamin supplements;


Classification kind code

11

Mark Details


Serial Number

1930746

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 55
on 22nd Feb 2022
Registered
Submitted for opposition 190
on 20th Oct 2021
Registration Pending
Submitted for opposition 191
on 20th Oct 2021
Registration Fee Notice Sent
Submitted for opposition 42
on 28th Jul 2021
Advertised
Submitted for opposition 27
on 29th Jun 2021
Approval Notice Sent
Submitted for opposition 26
on 29th Jun 2021
Approved
Submitted for opposition 22
on 22nd Jun 2021
Search Recorded
Submitted for opposition 31
on 19th Nov 2018
Formalized
Submitted for opposition 1
on 16th Nov 2018
Created
Submitted for opposition 30
on 15th Nov 2018
Filed